ETTA

AI platform, senolytics, small molecules

clearingsmall molecule

ettabiotechnology.com·United States·

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-F5KO

Projects

Senescent Cell-Clearing Lead Molecule

preclinical

drug program · medium

Develop a longevity medicine that clears senescent cells and addresses aging-related disease biology, including kidney aging.

Novel small-molecule senolytic therapeutic identified or evaluated through ETTA's SenoSmart platform.

ETTA states its first novel molecule lead safely and effectively clears senescent cells and reverses a marker of kidney aging and disease.

Reported to clear senescent cells and reverse a marker of kidney aging and disease; no clinical-stage data supplied.

SenoSmart Platform

undisclosed

platform · high

Evaluate longevity therapeutic candidates across molecules, gene mechanisms of action, tissue types, and criteria related to effectiveness, safety, metabolism, bioavailability, and clinical success.

AI-guided drug discovery platform assessing 300,000 molecules, 949 gene mechanisms of action, and 20 tissue types against therapeutic-success criteria.

Platform publicly described as ETTA's AI-guided longevity therapeutics discovery system.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence